SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma

Key Points • The SUMO pathway is activated in MM and its magnitude associated with progression and treatment resistance.• SUMO inhibition overcomes proteasome inhibitor resistance by blocking myeloma stress resilience, irrespective of p53 state.

[1]  S. Haas,et al.  Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer , 2022, The Journal of clinical investigation.

[2]  L. Bullinger,et al.  Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma , 2022, Nature communications.

[3]  J. Rip,et al.  Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model , 2022, Gut.

[4]  A. Baiker,et al.  Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphoma , 2022, Nature communications.

[5]  Gary D Bader,et al.  The reactome pathway knowledgebase 2022 , 2021, Nucleic Acids Res..

[6]  F. Pichiorri,et al.  SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma , 2021, Journal of experimental & clinical cancer research : CR.

[7]  J. Richter,et al.  Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams , 2022, Frontiers in Oncology.

[8]  F. Bassermann,et al.  Multiple Myeloma: Molecular Pathogenesis and Disease Evolution , 2021, Oncology Research and Treatment.

[9]  Steven S. Langston,et al.  A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models , 2021, Science Translational Medicine.

[10]  L. Sistonen,et al.  Therapeutic Potential of Targeting the SUMO Pathway in Cancer , 2021, Cancers.

[11]  Colin J. Daniel,et al.  Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo , 2021, Nature Chemical Biology.

[12]  Xingyue He,et al.  Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer. , 2021, Journal of medicinal chemistry.

[13]  B. Kuster,et al.  The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma , 2021, Molecular cell.

[14]  A. Vertegaal,et al.  Targeting SUMO Signaling to Wrestle Cancer. , 2020, Trends in cancer.

[15]  M. Wirth,et al.  Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy , 2020, Cancers.

[16]  Shaji K. Kumar,et al.  Multiple myeloma current treatment algorithms , 2020, Blood Cancer Journal.

[17]  T. Aittokallio,et al.  SynergyFinder 2.0: visual analytics of multi-drug combination synergies , 2020, Nucleic Acids Res..

[18]  Chun Young Im,et al.  Function of PIN1 in Cancer Development and Its Inhibitors as Cancer Therapeutics , 2020, Frontiers in Cell and Developmental Biology.

[19]  W. Weichert,et al.  SUMO pathway inhibition targets an aggressive pancreatic cancer subtype , 2020, Gut.

[20]  Peng Shu,et al.  Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation , 2020, Scientific Reports.

[21]  S. Müller,et al.  The SUMO Isopeptidase SENP6 Functions as a Rheostat of Chromatin Residency in Genome Maintenance and Chromosome Dynamics. , 2019, Cell reports.

[22]  B. Quesnel,et al.  Deregulation and Targeting of TP53 Pathway in Multiple Myeloma , 2019, Front. Oncol..

[23]  Shiming Yang,et al.  Prolyl isomerase Pin1: a promoter of cancer and a target for therapy , 2018, Cell Death & Disease.

[24]  T. Efferth,et al.  Drug targets and resistance mechanisms in multiple myeloma , 2018 .

[25]  S. Müller,et al.  SUMO-specific proteases and isopeptidases of the SENP family at a glance , 2018, Journal of Cell Science.

[26]  J. Laubach,et al.  The proteasome and proteasome inhibitors in multiple myeloma , 2017, Cancer and Metastasis Reviews.

[27]  A. Dejean,et al.  SUMO and the robustness of cancer , 2017, Nature Reviews Cancer.

[28]  Lars J Jensen,et al.  Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation , 2017, Nature Structural &Molecular Biology.

[29]  Correction: SENP1 deSUMOylates and Regulates Pin1 Protein Activity and Cellular Function. , 2017, Cancer Research.

[30]  J. Weissman,et al.  Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits , 2015, eLife.

[31]  D. Green,et al.  Pin1-Induced Proline Isomerization in Cytosolic p53 Mediates BAX Activation and Apoptosis. , 2015, Molecular cell.

[32]  A. Vertegaal,et al.  Mapping the SUMOylated landscape , 2015, The FEBS journal.

[33]  Z. Xiao,et al.  Pin1 modulates p63α protein stability in regulation of cell survival, proliferation and tumor formation , 2013, Cell Death and Disease.

[34]  H. Shih,et al.  SENP1 deSUMOylates and regulates Pin1 protein activity and cellular function. , 2013, Cancer research.

[35]  D. Durocher,et al.  Regulation of DNA damage responses by ubiquitin and SUMO. , 2013, Molecular cell.

[36]  Parantu K. Shah,et al.  A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. , 2012, Cancer cell.

[37]  E. Yeh,et al.  SUMOylation and de‐SUMOylation in response to DNA damage , 2011, FEBS letters.

[38]  Antonio Rosato,et al.  A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. , 2011, Cancer cell.

[39]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[40]  S. Lonial,et al.  Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. , 2010, Blood.

[41]  A. Levine,et al.  The origins and evolution of the p53 family of genes. , 2010, Cold Spring Harbor perspectives in biology.

[42]  Bart Barlogie,et al.  The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. , 2010, Blood.

[43]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[44]  A. Joerger,et al.  Conservation of DNA-binding specificity and oligomerisation properties within the p53 family , 2009, BMC Genomics.

[45]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[46]  Xin Lu,et al.  The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP , 2007, Nature Structural &Molecular Biology.

[47]  S. Minucci,et al.  Protein Kinase C ß and Prolyl Isomerase 1 Regulate Mitochondrial Effects of the Life-Span Determinant p66Shc , 2007, Science.

[48]  R. Fonseca,et al.  Clinical significance of TP53 mutation in myeloma , 2007, Leukemia.

[49]  I. Watson,et al.  Ubiquitin and ubiquitin-like modifications of the p53 family. , 2006, Neoplasia.

[50]  F. Zhan,et al.  Prognostic value of Cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations , 2006, Leukemia.

[51]  Ronald T. Hay,et al.  The Protein Stability and Transcriptional Activity of p63α are Regulated by SUMO-1 Conjugation , 2005, Cell cycle.

[52]  Guojun Wu,et al.  Altered Sumoylation of p63α Contributes to the Split-Hand/Foot Malformation Phenotype , 2004, Cell cycle.

[53]  R. Mantovani,et al.  Pin1 links the activities of c-Abl and p300 in regulating p73 function. , 2004, Molecular cell.

[54]  S. Müller,et al.  SUMO: a regulator of gene expression and genome integrity , 2004, Oncogene.

[55]  S. Douc-Rasy,et al.  TP53 family members and human cancers , 2003, Human mutation.

[56]  S. Müller,et al.  Members of the PIAS family act as SUMO ligases for c-Jun and p53 and repress p53 activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Kaghad,et al.  Covalent modification of p73alpha by SUMO-1. Two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. , 2000, The Journal of biological chemistry.

[58]  P. Sonneveld,et al.  Drug resistance in multiple myeloma. , 1999, Seminars in hematology.

[59]  T. Bestebroer,et al.  Application of a Mycoplasma group-specific PCR for monitoring decontamination of Mycoplasma-infected Chlamydia sp. strains , 1996, Applied and environmental microbiology.

[60]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.